Chesapeake IRB Announces Acquisition of Goodwyn IRB - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Chesapeake IRB Announces Acquisition of Goodwyn IRB

Source: Company News Release

Chesapeake IRB, announced it has completed the acquisition of Goodwyn IRB.

Goodwyn IRB, headquartered in Cincinnati, Ohio, and Chesapeake IRB, headquartered in Columbia, Maryland are providers of federally mandated institutional review board (“IRB”) services to pharmaceutical, biotech and medical device companies, universities, academic medical centers, hospital systems, governmental entities and others required to use IRB services to assure the protection of rights and the welfare of human subjects participating in research.

Felix Gyi, Founder and CEO of Chesapeake IRB, said, “We are excited to acquire Goodwyn IRB. Their operational expertise and commitment to human protection mirrors our own and will be an asset as we continue to build Chesapeake’s market presence as a leading independent IRB.”

Ellen Kelso, Founder and CEO of Goodwyn IRB, said “Goodwyn IRB is very pleased to be owned by Chesapeake IRB. We will share best practices across the firms while continuing to offer exceptional institutional review board services and human protection to our clients. They will now be able to utilize Chesapeake’s Center for IRB Intelligence (CIRBI) and have real time 24x7 access to all study documents.”

Elyse Summers, President and CEO, Association for the Accreditation of Human Research Protection Programs, commented “AAHRPP is delighted that two AAHRPP accredited, highly respected, independent IRBs have found the common ground of accreditation as a leverage point to create an enhanced organization.”

Goulston & Storrs served as counsel to Chesapeake IRB. Vorys served as counsel to Goodwyn IRB. Madison Capital Funding LLC provided financing to support the transaction.

For questions regarding Chesapeake IRB or Goodwyn IRB please contact:

Ruth Boulter – Vice President Business Development, Chesapeake IRB (609) 731-8786

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here